neurons from downstream regions? To address these questions, one certainly needs to first answer how adult-born neurons mechanistically contribute to brain functions, which remains the holy grail of the field and may require direct examination of newborn granule cells during behavior in vivo. Second, what is the mechanism underlying connectivity changes in response to experience? Does it depend on the activity of newborn neurons or presynaptic partners? Or is it simply a secondary effect of the altered systemic environment, for example, more secreted neurotrophic factors? Third, is the postsynaptic innervation of adult-born neurons to hilar neurons, CA3 neurons, and maybe others also experience dependent? The answer to these questions may facilitate a complete understanding of adult neurogenesis function. Forth, how do other experiences impact the integration process? For instance, does stress, which negatively regulates the generation and survival of newborn neurons (Christian et al., 2014) , affect the number of presynaptic partners? It is of note that laboratory mice are typically housed in a non-enriched environment as compared to their natural habitats. Therefore, the observed pattern in EE mice may mimic the natural pattern in wild animals, while the laboratory environment renders it less complex. Other pathological conditions, such as epileptic seizure and disease-causing gene mutations (e.g., mutations in Fmrp or Disc1), all lead to aberrant development of adult-born neurons (Christian et al., 2014) . Understanding how potential deficits in the connectivity of adultborn neurons under these conditions contribute to the brain dysfunctions will certainly be of broad interest to the society in general.
TRPA1 and TRPV1 are ion channels crucial for pain sensation. In this issue of Neuron, Weng et al. (2015) demonstrate that the activity of TRPA1-TRPV1 heteromers is governed by Tmem100 and that disabling Tmem100 may be a novel pharmacologic strategy to combat pain. drug targets and how they contribute to pain behaviors.
Many molecules have been implicated in contributing to pain sensations, but no family of transduction proteins has been studied as extensively as the Transient Receptor Potential (TRP) ion channels (Julius, 2013) . These channels are activated in response to a variety of chemical, thermal, and mechanical stimuli. Specifically, the TRP Vanilloid 1 (TRPV1) and TRP Ankyrin 1 (TRPA1) channels have been intensely studied based on the crucial roles they seem to play in the pain response. Indeed, genetic knockouts of these genes in mice lead to significant reductions in pain behaviors, buoying the argument that they are critical for pain sensation (Caterina et al., 2000; Kwan et al., 2006) .
Based on these strong data in rodent models, pharmaceutical companies quickly raced to develop antagonists of TRPA1 and TRPV1 that could be used clinically to limit the pain suffered by millions of people around the world. Unfortunately, like many drugs that pass preclinical trials, antagonists of TRPV1 have so far proven to be unsatisfactory for patient populations due to side effects such as hyperthermia and prevention of protective noxious heat sensation, and TRPA1 antagonists, while showing some signs of promise in clinical trials, have yet to move past phase II clinical trials (Kaneko and Szallasi, 2014) . Some pharmaceutical companies have even shelved research and development on TRPA1 and TRPV1 as pain targets due to these barriers. Thus, new modes of reducing the activity of TRP channels like TRPV1 and TRPA1 must be considered if they are to be used as suitable pharmacological pain targets.
Since the interaction between TRPA1 and TRPV1 has been shown to be important for their functional activity (Akopian, 2011) , one potential way to target these proteins is to disrupt their interactions with each other. Although some research has examined whether TRPA1 and TRPV1 interact via signaling pathways (Akopian, 2011) , other studies have shown that TRPA1 and TRPV1 physically interact via the formation of heteromers and that these heteromers confer distinct properties to native sensory neurons (Fischer et al., 2014; Salas et al., 2009; Staruschenko et al., 2010) . Therefore, targeting the formation of TRPA1/V1 heteromers or the interactions of these two ion channels when in complex presents a novel method for preventing TRP-mediated pain.
In this issue of Neuron, Weng et al. (2015) describe exciting research indicating that a little-studied protein, Tmem100, acts as a transmembrane adaptor protein to govern the functional and physical interaction between TRPA1 and TRPV1 in murine sensory neurons. Tmem100 is a two-transmembrane protein located in a wide variety of tissues, but importantly localizes its N and C termini to the intracellular side of the plasma membrane, allowing for interactions with other proteins. Based on experimental data using transgenic, molecular, and electrophysiological approaches, Weng et al. (2015) parse apart the effects of Tmem100 on TRPA1 and TRPV1 and have also helped reconcile incongruities in the literature between genetic knockouts of TRPA1 or TRPV1 and heterologous expression systems (Salas et al., 2009) .
Specifically, Weng et al. (2015) show that in the absence of Tmem100, TRPV1 forms a tight association with TRPA1 that greatly inhibits the activity of TRPA1 in response to chemical agonists but has no effect on TRPV1 agonism. In the presence of Tmem100, however, the physical association between TRPA1 and TRPV1 is loosened, leading to reduced inhibition of TRPA1, thereby allowing TRPA1 to have increased open probabilities in response to chemical agonists. Through the use of targeted mutations, Weng et al. (2015) then demonstrate that the regulation of this interaction depends critically on a KRR motif in the C terminus of Tmem100 and that mutation of just this three amino acid sequence to a series of three glutamines actually results in a stronger inhibition of TRPA1 by TRPV1. Thus, modifications to a small part of the C terminus of Tmem100 provide a novel mode of TRPA1 inhibition.
Critically, these results also carry over to the behavioral level, as Tmem100 À/À animals show reductions in mechanical pain behavior following inflammatory injury. Additionally, injection of a cell permeable peptide (CPP) consisting of the mutated C terminus of Tmem100 is able to partially ameliorate pain behaviors, opening the door for the use of this molecule as a novel therapeutic (Figure 1) . Given that the CPP was injected subcutaneously, these results also suggest that the Tmem100 CPP could serve as a relatively non-invasive mode of pain inhibition with fewer side effects due to local injection at the stimulus transduction site. Importantly, basal mechanosensitivity and thermal sensitivity (both heat and cold) are not affected by genetic deletion of Tmem100 or injection of the cell permeable peptide. Since off-target thermoregulatory effects and blunting of normal noxious sensation were two of the primary reasons that inhibitors of TRPA1 and TRPV1 did not pass clinical trials (Kaneko and Szallasi, 2014) , these data collectively support Tmem100 as a strong viable target for the alleviation of mechanical pain.
It is pertinent to emphasize that these experiments do not suggest that Tmem100 is a panacea for chronic pain conditions. On the behavioral level, pharmacologic or genetic targeting of Tmem100 is able to partially abrogate the reduction in paw withdrawal thresholds following short-term peripheral inflammation but is unable to completely normalize mechanical responses back to baseline. This suggests that, as would be expected, TRPA1 is not the only player mediating mechanical pain sensation following inflammatory injury. Additionally, the experiments presented in this issue of Neuron have only explored pain responses on an acute timescale following injury, and future studies must determine whether targeting Tmem100 represents an effective strategy for treating pain conditions on a chronic scale, which is a comparatively greater clinical problem than acute pain (Committee on Advancing Pain Research, Care, and Education, 2011). Finally, the effects of Tmem100 in other types of pain conditions (i.e., neuropathic pain) and in dorsal root ganglia from human tissue donors will need to be assessed for a full appreciation of the role of Tmem100 in pain sensation in patients.
Given the strong data in this manuscript indicating a role for Tmem100 in regulating the interaction between TRPV1 and TRPA1, another interesting question is what this molecule is doing in other tissues and also in the 40% of neurons that do not express either TRPA1 or TRPV1. One possibility is that Tmem100 interacts with other TRP channels in these neurons/ tissues, or, based on its ability to strongly regulate mechanical sensation, interacts with novel mechanotransducers.
This study did not look at mechanotransduction on the cellular level using patch-clamp recordings, and it will be quite compelling to examine how mechanically gated currents are affected by the interaction of TRPA1 and Tmem100. TRPA1 is thought to play a critical role in amplifying mechanical responses and may mediate slowly inactivating currents on the cellular level in native sensory neurons (Vilceanu and Stucky, 2010) but on its own is not thought to be directly mechanically gated. It has recently been demonstrated that the mechanically gated ion channel Piezo2 is not responsible for the mechanosensitivity of nociceptive afferents (Ranade et al., 2014) , in which TRPA1, TRPV1, and Tmem100 appear to be expressed. Therefore, further investigation of Tmem100's effects on mechanical currents and identification of additional binding partners may shed light on how TRPA1 contributes to mechanosensation and what proteins are ultimately responsible for the detection of mechanical stimuli by nociceptive afferents.
Also of note is that Tmem100 is expressed almost exclusively in peptidergic neurons. A recent study examining labeled lines for sensory coding in the periphery found that peptidergic neurons are disposable for mechanosensation, both under naive conditions and following inflammatory or neuropathic injury (McCoy et al., 2013) . Since peptidergic neurons play a significant role in mediating neurogenic inflammation following peripheral injury, it is possible that Tmem100 works in concert with TRPA1 and TRPV1 to mediate release of peptides such as Calcitonin Gene-Related Peptide (CGRP). CGRP could then act to either sensitize non-peptidergic afferents to mechanical stimuli directly or promote release of sensitizing agents from immune cells or keratinocytes to sensitize terminals indirectly. This would perhaps explain why genetic deletion of Tmem100 had no effect on basal mechanosensitivity, and future studies will be needed to resolve these discordant findings.
Ultimately, the findings presented here by Weng et al. (2015) provide new life for examining TRP channels as suitable pharmacological pain targets, and may be the impetus for new strategies to combat pathological pain sensation.
